FIELD: medicine.
SUBSTANCE: implementing the method of treating is ensured by sampling a mammal in need of reducing circulating galectin-3 levels, and performing a blood plasmapheresis in the above mammal. The plasmapheresis is performed to reduce circulating active gal-3 levels so as to remove at least ten percent of circulating gal-2 in individual's serum by means of the plasmapheresis. Using the invention provides binding and blocking gal-3 activity in the circulation or removing bulks of gal-3 from the circulation.
EFFECT: improving the existing conservative management, suppressing or reducing inflammation and fibrosis caused by the other ones, and enabling intervention into various painful conditions, which are not treated otherwise.
23 cl
| Title | Year | Author | Number |
|---|---|---|---|
| PLASMAPHERESIS DEVICE | 2014 |
|
RU2680677C2 |
| ANTI-GALECTIN-9 ANTIBODY AND USE THEREOF | 2021 |
|
RU2840501C1 |
| CENICRIVIROC FOR TREATING LIVER AND PERITONITIS DISEASES | 2015 |
|
RU2722641C2 |
| USE OF HEXAPEPTIDE TO REDUCE LEVELS OF EXTRACELLULAR HMGB1 PROTEIN IN INFLAMMATORY DISEASES | 2021 |
|
RU2813878C2 |
| TREATMENT OF HEART FAILURE IN HUMANS | 2020 |
|
RU2811365C2 |
| APPLYING OLTIPRAZ FOR PROPHYLAXIS AND TREATMENT OF LIVER FIBROSIS AND CIRRHOSIS AND OLTIPRAZ-CONTAINING PHARMACEUTICAL COMPOSITION | 2001 |
|
RU2258509C2 |
| HYBRID PROTEINS AND PROTEIN CONJUGATES BASED ON HEAT SHOCK PROTEIN-70 (HSP70) AND METHODS FOR USE THEREOF (VERSIONS) | 2012 |
|
RU2685867C2 |
| METHODS OF USING INTERLEUKIN-10 FOR TREATING DISEASES AND DISORDERS | 2014 |
|
RU2679889C2 |
| WOUND-HEALING AGENT FOR LOCAL APPLICATION | 1990 |
|
RU2023444C1 |
| 1-((3S,4R)-4-(3-FLUOROPHENYL)-1-(2-METHOXYETHYL)PYRROLIDIN-3-YL)-3-(4-METHYL-3-(2-METHYLPYRIMIDIN-5-YL)-1-PHENYL-1N-PYRAZOL-5-YL)UREA AS A TRKA KINASE INHIBITOR | 2015 |
|
RU2719489C2 |
